1. Differentiating Oncocytic Renal Tumors from Chromophobe Renal Cell Carcinoma: Comparison of Peak Early-phase Enhancement Ratio to Clinical Risk Factors and Rater Predictions
- Author
-
Hiten D. Patel, Kevin Huai, Nicholas Elliott, Deanna L. Thorson, Goran Rac, Maria M. Picken, Marcus L. Quek, Davide Bova, and Gopal N. Gupta
- Subjects
Kidney cancer ,Renal cell carcinoma ,Oncocytoma ,Oncocytic renal neoplasms ,Nephrectomy ,Computed tomography ,Diseases of the genitourinary system. Urology ,RC870-923 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Most surgically resected benign renal tumors are found to be oncocytomas or indolent hybrid oncocytic tumors, which are difficult to differentiate from chromophobe renal cell carcinoma (chRCC) on renal mass biopsy. Both often exhibit CD117+ staining. Objective: To evaluate the ability of the peak early-phase enhancement ratio (PEER) to distinguish oncocytomas from chRCC and compare its discrimination to traditional clinical risk factors and blinded clinical raters. Design, setting, and participants: This was a diagnostic case-control study of patients (2006–2020) with oncocytoma or chRCC according to surgical pathology. Intervention: Partial or radical nephrectomy. Outcome measurements and statistical analysis: Three clinical raters blinded to histology measured the PEER and the presence of stellate scar and predicted the final histology for each tumor. Averaged and individual PEER values were compared to surgical pathology and assessed for interobserver variability. Subanalyses were conducted for patients with confirmed CD117+ status. Results and limitations: For the 76 patients identified, PEER was higher among the 32 (42.1%) oncocytomas than among the 44 (57.9%) chRCCs (median 0.81 vs 0.43; p
- Published
- 2022
- Full Text
- View/download PDF